--(BUSINESS WIRE)--Blackstone Life Sciences and Anthos Therapeutics ... of abelacimab prompted the Independent Data Monitoring Committee to discontinue the study early. Results from AZALEA ...

Coya Therapeutics, Inc. has Treg therapies for neurodegenerative and autoimmune diseases, targeting ALS, FTD, AD, and PD. However, their lead candidate is now clearly COYA 302. This drug basically ...

Pliant Therapeutics has pumped the breaks on a midstage trial of its lead lung disease drug on the advice of its safety committee. The South San Francisco biotech has been evaluating 160-mg and ...

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United ...

LEXINGTON, Mass., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and ...

Jan. 28, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced positive initial data ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an early look at how receptive public investors could be to biotech listings ...

Justin Walsh, an analyst from JonesTrading, reiterated the Buy rating on Perspective Therapeutics (CATX – Research Report). The associated price target remains the same with $21.00. Justin Walsh ...

TransCode Therapeutics (RNAZ ... What To Know: The company’s Safety Review Committee approved the progression to the third cohort following a favorable review of safety and pharmacokinetic ...

Drug developers Aardvark Therapeutics, Aurion Biotech, Sonna Therapeutics, Metsera, and Odyssey Therapeutics are among the IPO hopefuls that have filed their paperwork in recent weeks. Maze ...

SAN DIEGO – Artiva Biotherapeutics, Inc. (ARTV), a biopharmaceutical company specializing in cellular immunotherapies with a current market capitalization of $135 million, has announced the ...